Key Events This Week
6 Apr: Week opens at Rs.981.50
7 Apr: Upgraded to Hold on technical and financial improvements
8 Apr: Formation of Golden Cross signalling potential bullish breakout
9 Apr: Technical momentum shifts to bullish amid mixed indicators
10 Apr: Week closes at Rs.1,000.65 (+1.95%)
7 April: Upgrade to Hold Reflects Technical and Financial Improvements
On 7 April, Strides Pharma Science Ltd was upgraded by MarketsMOJO from 'Sell' to 'Hold', driven by a marked improvement in technical indicators and robust financial performance. The stock gained 1.29% that day, closing at Rs.994.20, outperforming the Sensex's 0.50% rise. This upgrade was supported by a shift in weekly momentum indicators such as MACD and KST to bullish, despite mixed monthly signals.
Financially, the company reported a 133.64% growth in net profit for Q3 FY 2025-26, marking its tenth consecutive quarter of positive results. Operating profit to interest coverage ratio improved to 5.44 times, and ROCE for the half-year stood at 16.05%, signalling efficient capital utilisation. The debt-equity ratio improved to 0.67 times, reflecting a more conservative capital structure. Despite an 8.5% dip in annual profits, the consistent quarterly growth and attractive valuation metrics underpinned the upgrade.
8 April: Golden Cross Formation Signals Potential Bullish Breakout
On 8 April, the stock formed a Golden Cross, where the 50-day moving average crossed above the 200-day moving average, a classic bullish technical signal. Despite the stock declining 2.73% to close at Rs.967.10, this crossover suggested a potential long-term trend reversal. Daily moving averages turned bullish, supported by weekly MACD and KST indicators, while monthly MACD and RSI remained mildly bearish, indicating some caution among longer-term investors.
The Golden Cross was accompanied by bullish Bollinger Bands and On-Balance Volume trends on weekly and monthly charts, reinforcing the positive momentum. The stock’s valuation remained attractive with a P/E ratio of 16.04, well below the pharmaceuticals sector average of 31.26, highlighting potential undervaluation relative to peers.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
9 April: Technical Momentum Shifts to Bullish Amid Mixed Indicators
On 9 April, the stock rebounded strongly, gaining 3.02% to close at Rs.996.35, despite the Sensex declining 0.49%. This day marked a further upgrade in technical momentum from mildly bullish to bullish. Daily moving averages confirmed positive momentum, and weekly MACD and KST oscillators remained bullish. However, monthly MACD and RSI continued to signal caution, reflecting some underlying consolidation pressure.
Volume-based indicators such as On-Balance Volume were bullish on weekly and monthly charts, supporting the price gains. Dow Theory assessments also indicated mildly bullish trends across timeframes. Despite the short-term strength, the stock’s 2.73% decline the previous day highlighted volatility and profit-taking risks.
10 April: Week Closes with Modest Gain Amid Broader Market Rally
Strides Pharma closed the week on 10 April at Rs.1,000.65, up 0.43% from the previous day, while the Sensex surged 1.40%. The stock’s weekly gain of 1.95% lagged the Sensex’s 5.34% rally, reflecting mixed investor sentiment amid ongoing technical and fundamental developments. The stock remained well above its 52-week low of Rs.551.00 and near recent highs, supported by improved technical indicators and a stabilising financial outlook.
Considering Strides Pharma Science Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Daily Price Performance: Strides Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-06 | Rs.981.50 | - | 33,229.93 | - |
| 2026-04-07 | Rs.994.20 | +1.29% | 33,395.05 | +0.50% |
| 2026-04-08 | Rs.967.10 | -2.73% | 34,690.59 | +3.88% |
| 2026-04-09 | Rs.996.35 | +3.02% | 34,521.99 | -0.49% |
| 2026-04-10 | Rs.1,000.65 | +0.43% | 35,004.96 | +1.40% |
Key Takeaways
Positive Signals: The upgrade to Hold on 7 April was supported by strong quarterly financials and improved technical momentum, including bullish weekly MACD and KST indicators. The Golden Cross formation on 8 April is a significant long-term bullish signal, reinforced by bullish daily moving averages and volume trends. The stock’s valuation remains attractive relative to sector peers, with a P/E ratio of 16.04 versus the industry average of 31.26.
Cautionary Notes: Despite short-term bullish momentum, monthly technical indicators such as MACD and RSI remain mildly bearish, suggesting that longer-term confirmation of the uptrend is pending. The stock experienced a notable 2.73% decline on the day of the Golden Cross, indicating potential profit-taking and volatility. The stock’s weekly gain of 1.95% lagged the Sensex’s 5.34% rally, reflecting mixed investor sentiment amid broader market strength.
Conclusion
Strides Pharma Science Ltd demonstrated a week of mixed but cautiously optimistic developments. The upgrade to Hold and the Golden Cross formation signal improving technical and financial conditions, while valuation metrics remain supportive. However, the divergence between short-term bullish and longer-term cautious indicators suggests investors should monitor momentum closely. The stock’s relative underperformance versus the Sensex this week highlights the need for balanced risk management amid ongoing market volatility. Overall, Strides Pharma remains a stock with potential for further gains, contingent on confirmation of sustained technical strength and continued financial performance.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
